Navigation Links
Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
Date:7/1/2008

DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications.

Adrenalin is well known as the hormone that triggers the "fight or flight" reaction in response stress or danger. But Addrenex scientists recognized this hormone, and its counterpart in the brain, noradrenalin, as regulators of diverse physiologic functions -- from blood pressure to energy expenditure to thermostatic control.

"No other company is targeting adrenergic regulation as the root cause of conditions," said Moise Khayrallah, CEO of Addrenex. "We built our company to address a wide range of conditions whose symptoms are being partially managed by drugs currently on the market, but whose origins have never been specifically treated."

Last year the company efficiently advanced its first products, Clonicel(R) to treat attention deficit hyperactivity disorder and CloniBID to treat hypertension, into Phase 3 clinical trials. In July 2007, Addrenex licensed both products to Sciele Pharma for $6 million in upfront equity, $11 million in milestones, and future royalty payments on product sales.

One year later, the company has signed this second, larger deal, to include up to $27 million in development and regulatory milestones and future royalty payments on product sales. In addition, Sciele will pay all development costs.

"The partnership with Sciele is particularly rewarding because validates our work to date and confirms that our products may fill a critical gap in the treatment of debilitating conditions," said Khayrallah.

Addrenex began its foray into drug development by tweaking an existing drug, clonidine, to extend its benefits and reduce bothersome side effects. Company co-founder Joseph Horacek, M.D., originated the idea while seeking a better way to manage symptoms of aggression, hyperactivity and sleeplessness among his pediatric patients with ADHD.

The company quickly moved to advance its pipeline beyond traditional alpha-2 receptor agonists to compounds that would more selectively target specific subtypes of the alpha-2 receptor.

Alpha-2 receptors are present throughout the brain and body. They bind with adrenergic hormones and neurotransmitters such as adrenalin and noradrenalin to control a wide range of physiological functions. Malfunctions in the alpha-2 receptor pathway have been implicated in a wide range of conditions, including hypertension, pain, addiction, post traumatic stress disorder, menopausal symptoms, aggression and hyperactivity.

Yet few known drugs target the specific receptors involved in such conditions, Khayrallah said.

In December, Addrenex dramatically expanded its potential pipeline of drugs by licensing an existing library of 400 alpha-2 adrenergic compounds from UNeMed, the technology transfer arm at the University of Nebraska Medical Center. These compounds were originally developed by Procter & Gamble and later gifted to the university. Scientists at the university and Addrenex have already begun sifting through the data and examining compounds that appear to have selective affinity for the various alpha 2 receptor subtypes.

ADX415 was selected as a lead compound because of its receptor subtype profile and because it had undergone extensive preclinical and early clinical safety testing.

http://www.addrenex.com/


'/>"/>
SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
2. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
3. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Raptor Pharmaceuticals Closes $10 Million Private Placement
6. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
7. VIA Pharmaceuticals Set to Join Russell Microcap Index
8. Wyeth Pharmaceuticals Announces Organizational Change
9. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... When a downtown ... response was swift and efficient thanks to the continuing efforts of members of ... of more than 50 stakeholders, including officials from area counties and cities, Renewable ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... that it has appointed Vishwas Paralkar to the role of chief scientific officer. ... technology. He will report to Cybrexa’s president and CEO, Per Hellsund. , “I ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... examining the effects of exoskeleton-assisted walking on gait parameters and neuromuscular activity ... "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) was ...
(Date:9/19/2017)... ... September 19, 2017 , ... The latest ... dangerous step of sample prep for metals digestion—the addition of acids and reagents. ... affordable price. The system is ideal for any laboratory performing their own unique ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):